CLINICAL_TRIALS
trial_result
· 2022-03-07
Clinical Trial Update: Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty [Phase 2]
Summary
Phase IIb trial of Longeveron mesenchymal stem cells for aging frailty has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Longeveron Inc. | Conditions: Aging Frailty | Phase 2 | Status: COMPLETED